Oral Drug Delivery Solutions

  1. Sterile Formulation Development 7/1/2022

    With over 20 years of experience, PCI’s strength lies in our ability to manage products with unique challenges ranging from small molecules presenting with solubility issues or a labile molecule that is only stable as a liquid presentation for a short time.

  2. Formulation Strategies For Poorly Soluble Molecules 3/3/2022

    As the number of poorly soluble compounds continues to increase in the industry development pipeline, conventional formulation strategies may not be sufficient to achieve acceptable levels of solubility in the gastrointestinal tract and hence absorption into the systemic circulation.

  3. Pre-Formulation And Material Sciences 3/3/2022

    Our formulation development and material sciences experts have over 30 years’ experience in pre-formulation and solid state characterization.

  4. cGMP Aseptic Manufacturing And Sterile Fill-Finish 1/28/2022

    Experienced CDMOs will implement a cGMP aseptic manufacturing and sterile fill-finish policy to improve drug bioavailability. Aseptic fill-finish is a process in which the drug product, container, and container closure are sterilized separately and then integrated. Combining the drug, container, and closure in a clean room using special equipment that is self-contained in a sterile environment meets FDA guidelines related to cGMP.

  5. Rapid Development Through Phase I CTM 1/28/2022

    Ascendia works with discovery-stage pharmaceutical companies to provide lab-scale formulations suitable for pre-clinical testing. We conduct pre-formulation assessments, bioavailability modeling, and formulation approach comparisons. We provide trial formulations suitable for animal studies, toxicology studies, and cGMP clinical trial materials for Phase I studies.

  6. Formulations For Poorly Soluble And Low Bioavailability Drugs 1/28/2022

    Ascendia specializes in the development of market suitable formulations for poorly water soluble drug substances. Based on the pre-formulation data package and the delivery requirements for the product, we recommend a comprehensive formulation development strategy. We understand that each formulation is unique and must address the specific challenges associated with poor solubility, inadequate bioavailability, and/or unacceptable physical/chemical stability. We also understand the urgency companies have for progressing their pipeline, and our approach maximizes the probability of success by exploring multiple formulation options in parallel if necessary.

  7. Pharmaceutical Filling System For Non-Injectable Products: Ophthalmic, Nasal Sprays, Syrups: OFM 4/27/2021

    OFM automatic filling and closing machines are designed for pharmaceutical formulations, such as syrups, ophthalmic products, and nasal sprays either in glass or plastic containers.

  8. PBPK Predictive Modeling Services

    Early identification of potential absorption risks is critical for rapid and efficient drug development. Lonza's PBPK modeling services are designed to de-risk your drug development program.

  9. A Technology-Driven CDMO Delivering Integrated End-To-End Services

    Explore this interactive PDF with information about technologies & end-to-end integrated CDMO services provided by Adare Pharma Solutions.

  10. Find The Right Dosage Form To Suit Your Molecule

    Explore the importance of choosing the right partner to develop your Rx softgel drug.